Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease
暂无分享,去创建一个
S. Prusiner | W. DeGrado | L. Lannfelt | T. Bird | M. Ingelsson | C. Graff | C. Keene | J. Stöhr | J. Watts | Abby Oehler | K. Giles | S. V. van Duinen | Yibing Wu | S. Duinen | Carlo Condello | T. Lemmin | M. Nick | A. Maxwell | Christoffer D. Caro | Thomas Lemmin
[1] N. Fox,et al. Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions , 2017, Cell.
[2] S. Prusiner,et al. A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells. , 2017, Nature chemistry.
[3] John Collinge,et al. Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes , 2016, Nature.
[4] N. Cairns,et al. Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer’s Disease , 2016, Scientific Reports.
[5] S. Prusiner,et al. Structural Polymorphism of Alzheimer's β-Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study. , 2016, Journal of the American Chemical Society.
[6] Judianne Davis,et al. Cerebral vascular amyloid seeds drive amyloid β-protein fibril assembly with a distinct anti-parallel structure , 2016, Nature Communications.
[7] G. Antoni,et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.
[8] Nick C Fox,et al. Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease , 2015, The Journal of experimental medicine.
[9] S. Guan,et al. Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[10] A. Fagan,et al. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease , 2015, Neurology.
[11] Mathias Jucker,et al. Neurodegenerative diseases: expanding the prion concept. , 2015, Annual review of neuroscience.
[12] J. Haines,et al. Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. , 2015, Brain : a journal of neurology.
[13] J. Grutzendler,et al. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques , 2014, Nature Communications.
[14] R. Glockshuber,et al. Atomic-Resolution Three-Dimensional Structure of Amyloid β Fibrils Bearing the Osaka Mutation , 2014, Angewandte Chemie.
[15] D. Selkoe,et al. The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. , 2014, Human molecular genetics.
[16] S. Prusiner,et al. Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice , 2014, Proceedings of the National Academy of Sciences.
[17] S. Prusiner,et al. Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients , 2014, Proceedings of the National Academy of Sciences.
[18] L. Grinberg,et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.
[19] Ping Zhou,et al. Age-Dependent Neurovascular Dysfunction and Damage in a Mouse Model of Cerebral Amyloid Angiopathy , 2014, Stroke.
[20] H. Arai,et al. Use of a Benzimidazole Derivative BF-188 in Fluorescence Multispectral Imaging for Selective Visualization of Tau Protein Fibrils in the Alzheimer’s Disease Brain , 2014, Molecular Imaging and Biology.
[21] J. Clarimón,et al. Autosomal‐dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production , 2014, Journal of neurochemistry.
[22] Judianne Davis,et al. Cerebral microvascular rather than parenchymal amyloid-β protein pathology promotes early cognitive impairment in transgenic mice. , 2013, Journal of Alzheimer's disease : JAD.
[23] K. Nilsson,et al. Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice , 2013, EMBO reports.
[24] S. Prusiner,et al. Drug resistance confounding prion therapeutics , 2013, Proceedings of the National Academy of Sciences.
[25] G. Schellenberg,et al. The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ , 2013, Acta neuropathologica communications.
[26] M. Takeda,et al. γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. , 2013, Cell reports.
[27] M. Freedman,et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.
[28] J. Castilla,et al. De novo induction of amyloid-β deposition in vivo , 2012, Molecular Psychiatry.
[29] H. Wenschuh,et al. A comparative analysis of the aggregation behavior of amyloid‐β peptide variants , 2012, FEBS letters.
[30] B. Ghetti,et al. APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38 , 2012, Acta Neuropathologica.
[31] R. Nitsch,et al. Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation , 2012, Translational Psychiatry.
[32] A. Wall,et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.
[33] S. Prusiner,et al. A Unifying Role for Prions in Neurodegenerative Diseases , 2012, Science.
[34] Stephen J. DeArmond,et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.
[35] M. Lalowski,et al. The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ , 2012, Neurobiology of Aging.
[36] B. de Strooper,et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.
[37] R. Leigh,et al. Treatable neurological disorders misdiagnosed as Creutzfeldt‐Jakob disease , 2011, Annals of neurology.
[38] R. Tycko,et al. The Japanese mutant Aβ (ΔE22-Aβ(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Aβ(1-40) into atypical fibrils by ΔE22-Aβ(1-39). , 2011, Biochemistry.
[39] R. Tanzi,et al. The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.
[40] A. Bizzi,et al. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. , 2010, Archives of neurology.
[41] M. Gearing,et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease , 2010, Acta Neuropathologica.
[42] David W. Colby,et al. Design and construction of diverse mammalian prion strains , 2009, Proceedings of the National Academy of Sciences.
[43] Martin L. Duennwald,et al. A synergistic small molecule combination directly eradicates diverse prion strain structures , 2009, Nature chemical biology.
[44] R. Leapman,et al. Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure , 2009, Proceedings of the National Academy of Sciences.
[45] M. Staufenbiel,et al. E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. , 2009, The American journal of pathology.
[46] J. Wiltfang,et al. Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase* , 2008, Journal of Biological Chemistry.
[47] B. Ghetti,et al. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene] , 2008, FEBS letters.
[48] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[49] Yasuyoshi Watanabe,et al. A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.
[50] Richard M. Page,et al. Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation* , 2008, Journal of Biological Chemistry.
[51] Jonathan S. Weissman,et al. The structural basis of yeast prion strain variants , 2007, Nature.
[52] D. Walsh,et al. Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.
[53] Judianne Davis,et al. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double Aß in human AßPP transgenic mice , 2006, Neurobiology of Aging.
[54] Irene Otte-Höller,et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. , 2005, The American journal of pathology.
[55] Lingyun Zhu,et al. Non-invasive imaging of GFAP expression after neuronal damage in mice , 2004, Neuroscience Letters.
[56] Brian J Bacskai,et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[57] P. Lansbury,et al. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. , 2003, Journal of molecular biology.
[58] R. Roos,et al. Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles , 2001, Annals of neurology.
[59] T D Bird,et al. Neuropathological heterogeneity in Alzheimer’s disease: A study of 80 cases using principal components analysis , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.
[60] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[61] E. Storey,et al. The D178N (cis-129M) "fatal familial insomnia" mutation associated with diverse clinicopathologic phenotypes in an Australian kindred , 1997, Neurology.
[62] S. Prusiner,et al. Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity , 1996, Science.
[63] S. Prusiner,et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. , 1996, Genes & development.
[64] J. Hauw,et al. BSE transmission to macaques , 1996, Nature.
[65] J. Growdon,et al. Transmission and age-at-onset patterns in familial Alzheimer??s disease: evidence for heterogeneity , 1991 .
[66] S. M. Sumi,et al. Phenotypic heterogeneity in familial alzheimer's disease: A study of 24 kindreds , 1989, Annals of neurology.
[67] A. Paetau,et al. Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. , 2014, Journal of Alzheimer's disease : JAD.
[68] J. Laplanche,et al. Rapidly progressive Alzheimer's disease: a multicenter update. , 2012, Journal of Alzheimer's disease : JAD.
[69] B. Ghetti,et al. Neocortical variation of Abeta load in fully expressed, pure Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[70] Richard M. Page,et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. , 2008, The Journal of biological chemistry.
[71] C. Jack,et al. 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .
[72] C. Merril,et al. A rapid sensitive silver stain for polypeptides in polyacrylamide gels. , 1981, Analytical biochemistry.
[73] A. Rowan. Guide for the Care and Use of Laboratory Animals , 1979 .